Servier's $1.55B Sevasemten Misses Its Phase 2 GRAND CANYON Trial in Becker Muscular Dystrophy
- Sevasemten, the Becker muscular dystrophy drug Servier acquired for $1.55 billion upfront five months ago, missed its primary endpoint (North Star Ambulatory Assessment) and its secondary endpoints in the 18-month, placebo-controlled Phase 2 GRAND CANYON trial; safety and tolerability remained favourable.
- Servier says the results do not align with earlier findings, including the Phase 2 CANYON study, and is analysing the full dataset; the Phase 2 LYNX trial in Duchenne muscular dystrophy continues, due to complete in January 2027.
💡 Points Based on public reports
The earlier Phase 2 CANYON trial hit its biomarker (creatine kinase) endpoint but showed only a soft functional trend, so this outcome is the risk the price should have carried: a biomarker win is not a functional win. The next things to check are whether the dataset review finds a subgroup worth a new trial, and whether LYNX in Duchenne reads out any differently.